Use of type V phosphodiesterase inhibitors in the treatment of exercise induced pulmonary hemorrhage in the equine
The use of type V phosphodiesterase inhibitors as a novel independent therapeutic modality in the treatment of exercise induced pulmonary hemorrhage in equine is described. The type V phosphodiesterase inhibitor is injected into the horse intravenously as a stand-alone agent from about one-half hour to about seven (7) days prior to the onset of strenuous exercise.
1. A method for reducing the severity of pulmonary hemorrhaging in a performance horse during an exercise event, the method consisting essentially of the steps of:
a) providing a type V phosphodiesterase inhibitor;
b) determining a physiological acceptable quantity of the type V phosphodiesterase inhibitor to reduce pulmonary arterial pressure to about 90 mmHg, or less during an exercise event that produces pulmonary vasculature pressures of greater than 90 mmHg;
c) injecting the physiologically acceptable quantity of the type V phosphodiesterase inhibitor into the horse from about one-half hour to about 90 minutes prior to the exercise event; and
d) wherein a nitric oxide gas is not co-administered.
2. The method of claim 1 including selecting the type V phosphodiesterase inhibitor from the group consisting of (6R-trans)-6-(1,3-benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino[1′,2′:1,6]pyrido[3,4-b]indole-1,4-dione, 4-[2-eyhoxy-5-(4-ethylpiperazin-1-yl)sulfonyl-phenyl]-9-methyl-7-propyl 3,5,6,8-tetrazabicyclo[4,3,0]none 3,7,9 trien-2-one, 4-(3-chloro-4-methoxybenzyl)amino-1-(4-hydroxypiperidino)-6-phthalazinecarbonitrile monohydrochloride, (NA 1-(-6-chloro-4-(3,4-methylenedioxybenzyl)-aminoquinazolin-2-yl)-piperidine-4-carboxylate sesquihydrate, and mixtures thereof.
3. The method of claim 1 including determining the physiological acceptable quantity of the type V phosphodiesterase inhibitor by first determining the horse's weight.
4. The method of claim 1 including injecting the type V phosphodiesterase inhibitor in a dosage ranging from about 5 μgram/kilogram to about 200 μg/kilogram of horse weight.
5. A method for sustaining the production of cyclic 3′,5′-monophosphate in the lungs of a performance horse to reduce the severity of exercised induced pulmonary hemorrhaging during an exercise event, the method consisting essentially of the steps of:
a) providing a type V phosphodiesterase inhibitor;
b) determining, based on the horse's weight, a physiological acceptable quantity of the type V phosphodiesterase inhibitor to reduce pulmonary arterial pressure to about 90 mmHg, or less during an exercise event that produces pulmonary vasculature pressures of greater than 90 mmHg;
c) injecting the physiologically acceptable quantity of the type V phosphodiesterase inhibitor into the horse from about one-half hour to about 90 minutes prior to the exercise event to thereby maintain arterial pressure in the lungs at less than 80 mmHg throughout the duration of the exercise event; and
d) wherein a nitric oxide gas is not co-administered.
6. The method of claim 5 including selecting the type V phosphodiesterase inhibitor from the group consisting of (6R-trans)-6-(1,3-benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino [1′,2′:1,6]pyrido[3,4-b]indole-1,4-dione, 4-[2-eyhoxy-5-(4-ethylpiperazin-1-yl)sulfonyl-phenyl]-9-methyl-7-propyl 3,5,6,8-tetrazabicyclo[4,3,0]none 3,7,9 trien-2-one, 4-(3-chloro-4-methoxybenzyl)amino-1-(4-hydroxypiperidino)-6-phthalazinecarbonitrile monohydrochloride, (NA 1-(-6-chloro-4-(3,4-methylenedioxybenzyl)-aminoquinazolin-2-yl)-piperidine-4-carboxylate sesquihydrate, and mixtures thereof.
7. The method of claim 5 including injecting the type V phosphodiesterase inhibitor in a dosage ranging from about 5 μgram/kilogram of horse weight to about 200 μg/kg of horse weight.
8. A method for reducing the severity of exercised induced pulmonary hemorrhaging in a performance horse during an exercise event, the method consisting essentially of the steps of:
a) providing (NA 1-(-6-chloro-4-(3,4-methylenedioxybenzyl)-aminoquinazolin-2-yl)-piperidine-4-carboxylate sesquihydrate as a type V phosphodiesterase inhibitor;
b) determining a physiological acceptable quantity of the type V phosphodiesterase inhibitor to reduce pulmonary arterial pressure to about 90 mmHg, or less during an exercise event that produces pulmonary vasculature pressures greater than 90 mmHg;
c) injecting the physiologically acceptable quantity of the type V phosphodiesterase inhibitor into the horse from about one-half hour to about 90 minutes prior to the exercise event to thereby maintain arterial pressure in the lungs at less than 80 mmHg throughout the duration of the exercise event; and
d) wherein a nitric oxide gas is not co-administered.
9. The method of claim 8 including determining the physiological acceptable quantity of the type V phosphodiesterase inhibitor by first determining the horse's weight.
10. The method of claim 8 including injecting the type V phosphodiesterase inhibitor in a dosage ranging from about 5 μgram/kilogram of horse weight to about 200 μg/kg of horse weight.